ON DEMAND: Yale’s Review of Advances in Oncology Highlights from the ASCO® Annual Meeting 2021

Wednesday, July 7, 2021, 12:21 PM - Saturday, July 6, 2024, 1:21 PM

Due to budgetary and time constraints, many oncologists and researchers are unable to attend the American Society of Clinical Oncology (ASCO®) Annual Meeting and would benefit from this update. The ASCO® Annual Meeting is one of the premier meetings at which cutting edge information of vital importance to improving patient outcomes is presented. The goal of the Yale ASCO® Review 2021 is to provide hematologists, medical oncologists, and oncology nurses with current data and information presented at the Annual ASCO® Meeting.

Included Topics/Speakers:

Gastrointestinal Cancers - Pamela Kunz, MD

Case Discussion: Gastrointestinal Cancers
Kevin Billingsley, MD, MBA, Stacey Stein, MD, and Christina Gomez, MD
Moderated by: Pamela Kunz, MD Prostate and Bladder Cancers Daniel Petrylak, MD

Case Discussion: Genitourinary Cancers
Joseph Kim, MD, Michael Hurwitz, MD, PhD, and Michael Leapman, MD
Moderated by: Daniel Petrylak, MD

Breast Cancer - Maryam Lustberg, MD, MPH

Case Discussion: Breast Cancer
Lajos Pusztai, MD, Neal Fischbach, MD, Sarah Mougalian, MD
Moderated by: Maryam Lustberg, MD, MPH Lung Cancer Sarah Goldberg, MD, MPH

Case Discussion: Lung Cancer
Anne Chiang, MD, PhD, Gavitt Woodard, MD, Henry Park, MD, MPH
Moderated by: Sarah Goldberg, MD, MPH 

Keynote Lecture and Q&A Discussion     
50th Anniversary of the National Cancer Act Vincent T. DeVita, Jr., MD, and Roy S. Herbst, MD, PhD

Head & Neck Cancers - Barbara Burtness, MD

Case Discussion: Head & Neck Cancers
Aarti Bhatia, MD, Benjamin Judson, MD, and Melissa Young, MD, PhD
Moderated by: Barbara Burtness, MD

Melanoma and Renal Cell Carcinoma - Harriet Kluger, MD

Case Discussion: Melanoma and RCC
Mario Sznol, MD, Thuy Tran, MD, PhD, Kelly Olino, MD
Moderated by: Harriet Kluger, MD

1. Describe the current treatment options and updates in various cancer disease specialties
2. Discuss the development and outcomes of clinical cancer research trials and assess their relevance to patient care
3. Assess the emerging role of novel small molecules and antibodies in oncology

Physicians - $25
Nurses/PAs/Allied Health Professionals - $25
Non-Yale Residents/Fellows/Students - Complimentary
Yale Residents/Fellows/Students - Complimentary
YNHHS Faculty & Staff - Complimentary

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The Yale School of Medicine designates this enduring material for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure balance, independence, objectivity, and scientific rigor in all its educational programs.  All individuals involved in the development and presentation of Accredited Continuing Education activities are required to disclose all financial relationship(s) with ineligible companies that has occurred within the past 24 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. This information is disclosed to all activity participants prior to the commencement of the educational activity.

AMA PRA Category 1 Credits™ (4.00 hours), Non-Physician Attendance (4.00 hours)

Mitigation of Relevant Financial Relationships

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.